DVAX #DVAX — Dynavax Technologies Corp | Healthcare | Drug Manufacturers - Specialty & Generic | USA | NASD | August 25, 2025.Recent insider activity at Dynavax Technologies Corporation (DVAX) highlights a notable purchase by Scott Dunseeth Myers, a Director on the board. On August 22, 2025, Myers acquired 3,800 shares at an average price of $10.82 per share, amounting to a total investment of $41,116.
This transaction, disclosed via SEC Form 4 on August 25, 2025, at 08:50 AM EDT, increases his total holdings to 35,004 shares, reflecting insider confidence amid the stock's recent pullback.
SEC From 4:
sec.gov/Archives/edgar/data/1029142/000102914225000120/xslF345X05/wk-form4_1756126240.xml
Chart:
• (1D)
• (1W)
Examining the daily chart for DVAX, the stock is entrenched in a downtrend, trading below key moving averages (e.g., SMA 20 at ~$10.79, SMA 50 at ~$10.60, and SMA 200 at ~$11.82), with price action showing increased volatility and a recent drop to around $10.28-$10.53.
This setup introduces notable risks, including potential further downside if broader market sentiment in the healthcare sector weakens or if earnings catalysts fail to materialize.
However, the insider buy at these levels suggests a possible bottoming formation, and I estimate a modest upside potential of 5-10% in the near term, targeting resistance near $11-$11.50, contingent on positive volume confirmation and macroeconomic stability.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.